Advertisement
UK markets open in 2 hours 43 minutes

  • NIKKEI 225

    39,581.81
    -1.27 (-0.00%)
     

  • HANG SENG

    17,718.61
    +2.11 (+0.01%)
     

  • CRUDE OIL

    81.92
    +0.38 (+0.47%)
     

  • GOLD FUTURES

    2,335.90
    -3.70 (-0.16%)
     

  • DOW

    39,118.86
    -45.24 (-0.12%)
     

  • Bitcoin GBP

    50,036.82
    +2,030.01 (+4.23%)
     

  • CMC Crypto 200

    1,314.57
    +30.74 (+2.39%)
     

  • NASDAQ Composite

    17,732.60
    -126.10 (-0.71%)
     

  • UK FTSE All Share

    4,451.92
    -8.35 (-0.19%)
     
Property :

8 UK holiday home businesses you could buy now

A holiday let could be a very sound investment, providing a decent income, capital growth and — somewhere to escape

Novo Nordisk ends kidney disease trial, books $816 million impairment in Q2

Reuters
·1-min read
FILE PHOTO: Novo Nordisk hopes to launch experimental obesity drug this decade

COPENHAGEN (Reuters) -Novo Nordisk said on Wednesday it would recognise an impairment loss of about 5.7 billion Danish crowns ($816.72 million) in the second quarter of 2024, after its CLARION-CKD phase 3 trial failed to meet its primary endpoint.

Novo has decided to stop its CLARION-CKD trial because it did not meet its primary endpoint of change in systolic blood pressure from baseline to week 12, the company said in a statement.

The impairment is related to ocedurenone, a drug for uncontrolled hypertension with potential application in cardiovascular and kidney disease, that Novo acquired from KBP Biosciences in October 2023, the Danish pharma giant said.

($1 = 6.9791 Danish crowns)

(Reporting by Louise Breusch Rasmussen, editing by Essi Lehto)